We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Goldman Sachs (GS) May Continue Witnessing Revenue Pressure
Read MoreHide Full Article
On Sep 21, we issued an updated research report on The Goldman Sachs Group (GS - Free Report) . The company has been witnessing revenue pressure due to unfavorable market conditions. Also, its dependence on overseas revenues keeps us apprehensive.
On the other hand, the company has been successful in reducing expenses with the help of its cost-saving initiatives, but the pending legal hassles might weigh on its bottom-line growth.
Further, Goldman Sachs has been unsuccessful in gaining analysts confidence in terms of its future earnings. This is reflected by the slight downward revision in the Zacks Consensus Estimate for 2017 and 2018, over the last 30 days. The stock carries a Zacks Rank #4 (Sell).
Also, shares of Goldman Sachs have lost 3.4% year to date versus the industry’s rally of 2.7%.
Goldman Sachs’ net revenues have been declining due to lower client trading activities. Legislative challenges and low market volatility have been impacting its Institutional Client Services division. Further, management expects lower trading income in third-quarter 2017 due to the prevailing low volatility in the market.
The company is likely to face higher litigation provisions and legal expenses as it continues to face many investigations and lawsuits from investors and regulators.
However, Goldman Sachs remains committed to undertake expense-reduction initiatives. In 2016, the company successfully generated $1.6 billion run rate savings. Further, it is looking for opportunities that would aid growth.
Better-Ranked Stocks to Consider
Interactive Brokers Group’s (IBKR - Free Report) Zacks Consensus Estimate for current-year earnings was revised 3.4% upward for 2017, in the past 60 days. Also, its share price has increased 19.4% so far this year. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Raymond James Financial (RJF - Free Report) currently carries a Zacks Rank of 2. The stock’s current-year earnings estimates were revised slightly upward, over the past 60 days. Further, its shares have jumped 19.4% year to date.
Evercore Inc.’s (EVR - Free Report) Zacks Consensus Estimate for current-year earnings was revised 10.7% upward, over the last 60 days. Moreover, year to date, its shares have gained 12.6%. Also, it carries a Zacks Rank of 2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
Image: Bigstock
Goldman Sachs (GS) May Continue Witnessing Revenue Pressure
On Sep 21, we issued an updated research report on The Goldman Sachs Group (GS - Free Report) . The company has been witnessing revenue pressure due to unfavorable market conditions. Also, its dependence on overseas revenues keeps us apprehensive.
On the other hand, the company has been successful in reducing expenses with the help of its cost-saving initiatives, but the pending legal hassles might weigh on its bottom-line growth.
Further, Goldman Sachs has been unsuccessful in gaining analysts confidence in terms of its future earnings. This is reflected by the slight downward revision in the Zacks Consensus Estimate for 2017 and 2018, over the last 30 days. The stock carries a Zacks Rank #4 (Sell).
Also, shares of Goldman Sachs have lost 3.4% year to date versus the industry’s rally of 2.7%.
Goldman Sachs’ net revenues have been declining due to lower client trading activities. Legislative challenges and low market volatility have been impacting its Institutional Client Services division. Further, management expects lower trading income in third-quarter 2017 due to the prevailing low volatility in the market.
The company is likely to face higher litigation provisions and legal expenses as it continues to face many investigations and lawsuits from investors and regulators.
However, Goldman Sachs remains committed to undertake expense-reduction initiatives. In 2016, the company successfully generated $1.6 billion run rate savings. Further, it is looking for opportunities that would aid growth.
Better-Ranked Stocks to Consider
Interactive Brokers Group’s (IBKR - Free Report) Zacks Consensus Estimate for current-year earnings was revised 3.4% upward for 2017, in the past 60 days. Also, its share price has increased 19.4% so far this year. The stock carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Raymond James Financial (RJF - Free Report) currently carries a Zacks Rank of 2. The stock’s current-year earnings estimates were revised slightly upward, over the past 60 days. Further, its shares have jumped 19.4% year to date.
Evercore Inc.’s (EVR - Free Report) Zacks Consensus Estimate for current-year earnings was revised 10.7% upward, over the last 60 days. Moreover, year to date, its shares have gained 12.6%. Also, it carries a Zacks Rank of 2.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>